Movement Alert|Caris Life Sciences, Inc. Intraday Decline 4.19%, post-earnings pressure persists despite Q3 beat and raised outlook

Market Focus11-13

On November 13, Caris Life Sciences, Inc. fell 4.19% in Regular Trading, trading at $23.09 per share, with turnover of $5.2361 million.

The move followed continued post-earnings selling pressure even after the company reported third-quarter results above expectations and raised full-year revenue guidance.

Caris Life Sciences, Inc. previously reported Q3 EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also lifted full-year revenue guidance to $1.04 billion to $1.05 billion. Even so, EPS was below the prior-year level of $0.08, and recent analyst views remained mixed, with Buy and Neutral ratings both in place, suggesting investors remain cautious on valuation and the durability of growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment